SPECIAL NOTICE
A -- Development and Commercialization of Immunotoxin for Treatment of Focal Muscle Disorders
- Notice Date
- 5/27/2004
- Notice Type
- Special Notice
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, MD, 21702
- ZIP Code
- 21702
- Solicitation Number
- Reference-Number-ML-FMD-01
- Response Due
- 7/1/2004
- Archive Date
- 7/2/2004
- Point of Contact
- Bonnie Chamberlain, Marketing Coordinator, Phone (301)435-3134, Fax (301)402-2117, - Bonnie Chamberlain, Marketing Coordinator, Phone (301)435-3134, Fax (301)402-2117,
- E-Mail Address
-
chamberbo@mail.nih.gov, chamberbo@mail.nih.gov
- Description
- The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) seeks a Cooperative Research and Development Agreement (CRADA) Collaborator to work with NINDS in the development, manufacture and commercialization of immunotoxins for the treatment of focal movement disorders. NINDS is seeking a development and commercialization partner for GMP production and in vitro and in vivo testing of immunotoxins comprising anti-nicotinic acetylcholine receptor antibody (anti-ACR) conjugated to ricin or abrin. Potential Areas of Application Treatment of dystonias including cervical dystonia (spasmodic torticollis), focal hand dystonia, blepharospasm, and spasmodic dysphonia Treatment of strabismus Treatment of spasticity Treatment of wrinkles Treatment of sphincter spasms such an anismus Main Advantages of Technology/Invention: Longer duration of effect than botulinum toxin type A Specific for mature myofibers Can be used in patients who are refractory to treatment with botulinum toxin Current State of Development In vivo studies in animal models indicate that anti-ACR-ricin conjugate is effective in weakening both limb and eye muscles Further R&D Required: Produce GMP quality immunotoxin Screen immunotoxin for activity in vitro or in vivo Plan for clinical trials of immunotoxin Patent Status: Patent pending ( published as US PTO Application 20020081303 ) Licensing of technology available Submission Dates: Letter of interest should be received by July 1, 2004. Proposals will be reviewed in order of receipt Contact Information: Martha T. Lubet Ph.D. NINDS Technology Transfer by TTB/ NCI Phone:301 435-3120 E-mail lubetm@mail.nih.gov
- Record
- SN00593549-W 20040529/040527211821 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |